Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$107.43 USD
-0.89 (-0.82%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $107.77 +0.34 (0.32%) 7:12 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Jazz Pharmaceuticals (JAZZ) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$188.29 | $230.00 | $131.00 | 73.83% |
Price Target
Based on short-term price targets offered by 17 analysts, the average price target for Jazz Pharmaceuticals comes to $188.29. The forecasts range from a low of $131.00 to a high of $230.00. The average price target represents an increase of 73.83% from the last closing price of $108.32.
Analyst Price Targets (17)
Broker Rating
Jazz Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.56 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 18 brokerage firms. The current ABR compares to an ABR of 1.56 a month ago based on 18 recommendations.
Of the 18 recommendations deriving the current ABR, 12 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.67% and 11.11% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 11.11%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 12 | 12 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 4 | 4 | 4 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.56 | 1.56 | 1.56 | 1.56 | 1.56 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/20/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
3/20/2024 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
3/20/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
3/14/2024 | H.C. Wainwright & Co. | Oren Livnat | Strong Buy | Strong Buy |
2/29/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
1/3/2024 | Robert W. Baird & Co. | Joel L Beatty | Not Available | Strong Buy |
11/8/2023 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
9/29/2023 | Raymond James | Gary Nachman | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.56 |
ABR (Last week) | 1.56 |
# of Recs in ABR | 18 |
Average Target Price | $188.29 |
LT Growth Rate | 4.50% |
Industry | Medical - Drugs |
Industry Rank by ABR | 93 of 252 |
Current Quarter EPS Est: | 4.14 |